AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Care sought in Rwanda (intervention group)
Number of subjects: 1413
Study 31821210 — intervention group
Group type: COMPARATOR
Intervention: Care received in Sierra Leone (control group)
Number of subjects: 1413
Study 31821210 — intervention group
Group type: COMPARATOR
Intervention: Care sought in Sierra Leone (control group)
Number of subjects: 1413
Study 31821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for receiving care (multivariate analysis)
Number of subjects: 1413
Study 31821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for not receiving care (multivariate analysis)
Number of subjects: 1413
Study 31693803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (TAK-003)
Number of subjects: 20071
Study 31693803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20071
Study 28481726 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (neonatal schedule)
Number of subjects: 89
Study 28481726 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (infant schedule)
Number of subjects: 89
Study 28481726 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (both schedules)
Number of subjects: 89
Study 28481726 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine
Number of subjects: 89
Study 28481726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25954737 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg, three once-weekly doses)
Number of subjects: 219
Study 25954737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 23460821 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 16
Study 23460821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22082783 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 60
Study 22082783 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 60
Study 19114797 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shock
Number of subjects: 168
Study 19114797 — intervention group
Group type: EXPERIMENTAL
Intervention: History of chronic obstructive pulmonary disease (COPD)
Number of subjects: 168
Study 19114797 — intervention group
Group type: EXPERIMENTAL
Intervention: History of congestive heart failure
Number of subjects: 168
Study 19114797 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented ventricular tachycardia (VT) at the time of ICD implant
Number of subjects: 168
Study 19114797 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of anxiety
Number of subjects: 168
Study 17145460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic bracing
Number of subjects: 83
Study 17145460 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic taping
Number of subjects: 83
Study 12626849 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 61
Study 11739308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -15 mm Hg
Number of subjects: 10
Study 11739308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -20 mm Hg
Number of subjects: 10
Study 11739308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -10 mm Hg
Number of subjects: 10
Study 11739308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mm Hg
Number of subjects: 10
Study 11739308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -30 mm Hg
Number of subjects: 10
Study 8922489 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term bone marrow cultures in patients with essential thrombocythaemia and polycythaemia vera
Number of subjects: 11
Study 1565758 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium chloride (high sodium)
Number of subjects: 32
Study 1565758 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets (usual sodium)
Number of subjects: 32
Study 3892749 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride supplemented amalgam (Yata) containing 0.5% fluoride as stannous fluoride
Number of subjects: 196
Study 3892749 — intervention group
Group type: COMPARATOR
Intervention: Non gamma 2 amalgam (Amalcap)
Number of subjects: 196
Study 29882841 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D₃ daily
Number of subjects: 60
Study 29882841 — intervention group
Group type: COMPARATOR
Intervention: 50,000 IU vitamin D₃ monthly
Number of subjects: 60
Study 29882841 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 60
Study 27640797 — intervention group
Group type: COMPARATOR
Intervention: Artificial cycle group
Number of subjects: 572
Study 27640797 — intervention group
Group type: COMPARATOR
Intervention: Drospirenone and ethinylestradiol tablets group
Number of subjects: 572
Study 27640797 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate group
Number of subjects: 572
Study 27640797 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 572
Study 25948432 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) scheme
Number of subjects: 29
Study 25948432 — intervention group
Group type: COMPARATOR
Intervention: Traditional input-based funding (non-PBF)
Number of subjects: 29
Study 22684569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with tyrosine, lecithin, L‐glutamine and 5‐HTP, n=41
Number of subjects: 83
Study 22684569 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=42
Number of subjects: 83
Study 20170333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose budesonide/formoterol 160/4.5 microg x 2 inhalations (320/9 mug) twice daily
Number of subjects: 1225
Study 20170333 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose fluticasone propionate/salmeterol 250/50 microg twice daily
Number of subjects: 1225
Study 20170333 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable-dose budesonide/formoterol (adjustable from 320/9 microg twice daily to 320/9 microg once daily or 640/18 microg twice daily)
Number of subjects: 1225
Study 18693154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% and benzoyl peroxide 2.5% (adapalene/BPO)
Number of subjects: 0
Study 18693154 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1%
Number of subjects: 0
Study 18693154 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide 2.5%
Number of subjects: 0
Study 18693154 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel
Number of subjects: 0
Study 18693154 — intervention group
Group type: COMPARATOR
Intervention: BPO 10% gel
Number of subjects: 0
Study 18693154 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 0
Study 16036492 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement protocols involving multiple measurements and standardized techniques
Number of subjects: 3688
Study 16036492 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of operators and auditing of blood pressure measurement
Number of subjects: 3688
Study 16036492 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure recording protocols and elimination of digit preferences
Number of subjects: 3688
Study 12013059 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse with parental marital disruption
Number of subjects: 198
Study 12013059 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse without parental marital disruption
Number of subjects: 198
Study 12013059 — intervention group
Group type: COMPARATOR
Intervention: Parental marital disruption without physical abuse
Number of subjects: 198
Study 12013059 — intervention group
Group type: COMPARATOR
Intervention: Non-abused adolescents with parental marital disruption
Number of subjects: 198
Study 10211260 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 123
Study 10211260 — intervention group
Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 123
Study 7881965 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate modified radical mastectomy
Number of subjects: 79
Study 7881965 — intervention group
Group type: COMPARATOR
Intervention: Initial cytotoxic or endocrine treatment followed by mastectomy
Number of subjects: 79
Study 7881965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Immediate modified radical mastectomy and Initial cytotoxic or endocrine treatment)
Number of subjects: 79
Study 7881965 — intervention group
Group type: COMPARATOR
Intervention: Primary systemic therapy
Number of subjects: 79
Study 7881965 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 79
Study 2229749 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 42
Study 2229749 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 42
Study 2229749 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted segments
Number of subjects: 42
Study 2229749 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted segments
Number of subjects: 42
Study 2229749 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted arteries
Number of subjects: 42
Study 2229749 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted arteries
Number of subjects: 42
Study 2229749 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 42
Study 2229749 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal segments in grafted vessels
Number of subjects: 42
Study 2229749 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal segments in grafted vessels
Number of subjects: 42
Study 2229749 — intervention group
Group type: EXPERIMENTAL
Intervention: Segments with occluded grafts
Number of subjects: 42
Study 2229749 — intervention group
Group type: COMPARATOR
Intervention: Segments with patent grafts
Number of subjects: 42
Study 353121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate 1600 mg daily
Number of subjects: 58
Study 353121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 7137535 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 12
Study 7137535 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 12
Study 7137535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7137535 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 and Terbutaline
Number of subjects: 12
Study 30614616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 0
Study 30614616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 0
Study 30614616 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Glimepiride
Number of subjects: 0
Study 29474935 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler® M3 (1.5 mg terbutaline)
Number of subjects: 60
Study 29474935 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler® M2 (1.5 mg terbutaline)
Number of subjects: 60
Study 29474935 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler® M3 (0.5 mg terbutaline)
Number of subjects: 60
Study 29474935 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler® M2 (0.5 mg terbutaline)
Number of subjects: 60
Study 27420578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 97
Study 27420578 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 97
Study 24698298 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (group A, n=61)
Number of subjects: 249
Study 24698298 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (group B, n=92)
Number of subjects: 249
Study 24698298 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (group C, n=96)
Number of subjects: 249
Study 22490873 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor mental health (mental health index score ≤60)
Number of subjects: 0
Study 20216468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (40 mg)
Number of subjects: 22
Study 20216468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18179313 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 40
Study 18179313 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 16330394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.97+/‐0.12 g/kg body weight)
Number of subjects: 10
Study 16330394 — intervention group
Group type: COMPARATOR
Intervention: Juice (placebo)
Number of subjects: 10
Study 12192890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 20
Study 12192890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9811982 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament retention (n = 11)
Number of subjects: 20
Study 9811982 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior stabilizing articular surface (n = 9)
Number of subjects: 20
Study 9811982 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 7898521 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy
Number of subjects: 106
Study 7898521 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 106
Study 2716162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release PPA hydrochloride 75 mg once per day
Number of subjects: 881
Study 2716162 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release PPA hydrochloride 25 mg three times per day
Number of subjects: 881
Study 2716162 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules three times per day
Number of subjects: 881
Study 564503 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant walker training, 2 hours per day starting at 300 days of age
Number of subjects: 12
Study 564503 — intervention group
Group type: COMPARATOR
Intervention: No special training (control group)
Number of subjects: 12
Study 31721042 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple stimuli with varying degrees of target-distractor similarity
Number of subjects: 0
Study 30676827 — intervention group
Group type: COMPARATOR
Intervention: COD training without external load (COD-0)
Number of subjects: 54
Study 30676827 — intervention group
Group type: EXPERIMENTAL
Intervention: COD training with a 12.5% body-mass external load (COD-12.5)
Number of subjects: 54
Study 30676827 — intervention group
Group type: EXPERIMENTAL
Intervention: COD training with a 50% body-mass external load (COD-50)
Number of subjects: 54
Study 28182127 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (23.75 or 47.5 mg, qd PO, dose escalated with 23.75 mg each time until target heart rate [HR] <70 bpm was achieved)
Number of subjects: 154
Study 28182127 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 154
Study 26556275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin, ciprofloxacin, amoxicillin, and minocycline
Number of subjects: 66
Study 26556275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23799683 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered web-based computer intervention
Number of subjects: 0
Study 23799683 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 21326107 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone at 0.2 μg·kg(‐1)·min(‐1)
Number of subjects: 3
Study 21326107 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone at 0.4 μg·kg(‐1)·min(‐1)
Number of subjects: 3
Study 21326107 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 μg·kg(‐1)·min(‐1))
Number of subjects: 3
Study 19057445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 5 mg/kg/day in four divided doses for 7 days
Number of subjects: 38
Study 19057445 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (similar amount in a similar manner) for 7 days
Number of subjects: 38
Study 19057445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 17721240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of propofol (2.5 mg/kg)
Number of subjects: 61
Study 17721240 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-, 2-, or 3-min infusion of propofol (2.5 mg/kg)
Number of subjects: 61
Study 11027910 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (titrated from 1,200 mg/day to a maximum of 2,400 mg/day)
Number of subjects: 25
Study 11027910 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (titrated from 30 mg/day to a maximum of 90 mg/day)
Number of subjects: 25
Study 11027910 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 25
Study 11027910 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 25
Study 9410677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic cholangiography (IOC) attempted in 138 patients
Number of subjects: 275
Study 9410677 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative fluoroscopic cholangiography (IOC) in 137 patients
Number of subjects: 275
Study 9410677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic cholangiography (IOC)
Number of subjects: 275
Study 8450987 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with antiepileptic drugs (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Number of subjects: 397
Study 8450987 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with the same antiepileptic drugs
Number of subjects: 397
Study 3708118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 12
Study 3708118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12
Study 3708118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 12
Study 3708118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 12
Study 3708118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (all doses)
Number of subjects: 12
Study 31684857 — intervention group
Group type: EXPERIMENTAL
Intervention: Models based on pathway scores
Number of subjects: 0
Study 31684857 — intervention group
Group type: EXPERIMENTAL
Intervention: Models based on true pathway mappings
Number of subjects: 0
Study 31684857 — intervention group
Group type: COMPARATOR
Intervention: Models based on randomised pathway mappings
Number of subjects: 0
Study 28141545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1000 mg containing 180 mg EPA and 120 mg DHA)
Number of subjects: 150
Study 28141545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 28141545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 150
Study 24756976 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF)
Number of subjects: 63
Study 24756976 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 63
Study 23103775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg kg(‐1) (Group P)
Number of subjects: 222
Study 23103775 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 µg kg(‐1) (Group F)
Number of subjects: 222
Study 23103775 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 222
Study 22145448 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 8
Study 22145448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22145448 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 8
Study 19451819 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone replacement therapy
Number of subjects: 16608
Study 19451819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 17457713 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 femoral nerve block with 40 ml of ropivacaine 0.375% (Group R)
Number of subjects: 34
Study 17457713 — intervention group
Group type: COMPARATOR
Intervention: Morphine loading dose of 2 mg (Group S)
Number of subjects: 34
Study 12637461 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide (500 mg/d for the first 2 years)
Number of subjects: 2021
Study 12637461 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (40 mg/d for the first 2 years, then 20 mg/d for 3 years)
Number of subjects: 2021
Study 12637461 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide
Number of subjects: 2021
Study 12637461 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2021
Study 10925565 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10(‐4)% fentanyl (10‐20 mL) administered epidurally during early first-stage labor (Group A)
Number of subjects: 318
Study 10925565 — intervention group
Group type: COMPARATOR
Intervention: No analgesic during the early first stage of labor (Group B)
Number of subjects: 318
Study 10925565 — intervention group
Group type: COMPARATOR
Intervention: No analgesic during the entire labor course (Group C)
Number of subjects: 318
Study 8898515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle exercise packet (LEP)
Number of subjects: 113
Study 8898515 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise packet (SEP)
Number of subjects: 113
Study 8898515 — intervention group
Group type: COMPARATOR
Intervention: Control packet
Number of subjects: 113
Study 1381024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 20
Study 1381024 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 20
Study 1381024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20